Certara CFO John Gallagher to Resign in 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Source: NASDAQ.COM
- Executive Change: Certara's CFO John Gallagher has announced his resignation effective July 14, 2026, indicating potential instability at the executive level, which may impact investor confidence.
- Interim Appointment: Faiz Mohammed will serve as interim CFO; currently the Senior VP of Finance, he brings over 25 years of finance and accounting experience, expected to provide transitional support during this period.
- Stock Price Fluctuation: Certara shares closed at $6.03, down 0.33%, and traded at $5.88 in the overnight market, reflecting a 2.49% decline, indicating market concerns regarding the executive change.
- Market Reaction: The resignation news may prompt investors to reassess Certara's future financial performance, potentially putting pressure on the stock price in the short term and affecting the company's competitiveness in the biotech sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CERT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CERT
Wall Street analysts forecast CERT stock price to rise
11 Analyst Rating
7 Buy
4 Hold
0 Sell
Moderate Buy
Current: 6.030
Low
9.00
Averages
12.11
High
16.00
Current: 6.030
Low
9.00
Averages
12.11
High
16.00
About CERT
Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development (MIDD) in the global biopharmaceutical industry. It accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. It delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. It offers both mechanistic and empirical biosimulation solutions, providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,600 biopharmaceutical companies, academic institutions and biotech companies across 70 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investigation Launched into Certara by Law Firm for Investor Claims
- Declining Financial Performance: Certara reported a 4% year-over-year decline in services revenue to $57.2 million and a 14% drop in services bookings to $66.6 million in its Q1 2026 results, raising concerns among investors about potential future revenue growth challenges.
- Weak Customer Performance: The company noted softer performance from Tier 1 customers in MIDD services, describing overall service performance as 'mixed', indicating challenges in maintaining customer relationships and market competitiveness, which could impact its market share.
- Exit from Regulatory Business: Certara announced its exit from the regulatory business within its services segment, a strategic shift that may further affect the company's revenue structure and business diversity, increasing uncertainty regarding its future growth prospects.
- Significant Stock Price Drop: Following the earnings report, Certara's stock price plummeted from $6.31 to $5.13 per share, a decline of approximately 19%, reflecting market concerns over the company's financial health and potentially diminishing investor confidence.
See More
Investigation into Certara Investor Losses Announced
- Financial Performance Decline: Certara reported a 4% year-over-year decline in services revenue to $57.2 million and a 14% drop in services bookings to $66.6 million in Q1 2026, indicating weak performance among Tier 1 customers that could hinder future revenue growth.
- Execution Challenges: The company acknowledged execution and go-to-market challenges in its services business, with inconsistencies between software and services performance, reflecting difficulties in business integration and responsiveness to customer demands, which may erode investor confidence.
- Executive Transition: On June 17, 2026, Certara announced CFO John Gallagher's resignation effective July 14, 2026, with Faiz Mohammed stepping in as Interim CFO, raising concerns about management stability that could further impact stock prices.
- Legal Investigation Initiated: Johnson Fistel is investigating whether Certara complied with federal securities laws, and if investors suffered losses from holding Certara stock, they may seek compensation through legal channels, potentially damaging the company's reputation and shareholder trust.
See More
Certara CFO John Gallagher to Resign in 2026
- Executive Change: Certara's CFO John Gallagher has announced his resignation effective July 14, 2026, indicating potential instability at the executive level, which may impact investor confidence.
- Interim Appointment: Faiz Mohammed will serve as interim CFO; currently the Senior VP of Finance, he brings over 25 years of finance and accounting experience, expected to provide transitional support during this period.
- Stock Price Fluctuation: Certara shares closed at $6.03, down 0.33%, and traded at $5.88 in the overnight market, reflecting a 2.49% decline, indicating market concerns regarding the executive change.
- Market Reaction: The resignation news may prompt investors to reassess Certara's future financial performance, potentially putting pressure on the stock price in the short term and affecting the company's competitiveness in the biotech sector.
See More
Certara CFO John Gallagher Announces Resignation Effective July 14, 2026
- Executive Change: Certara's CFO John Gallagher has announced his resignation effective July 14, 2026, indicating a significant shift in the company's financial leadership that could impact investor confidence and the stability of its financial strategy.
- Interim Leadership: Following Gallagher's departure, Faiz Mohammed, Certara's Senior Vice President of Finance and Treasurer, will serve as interim CFO, ensuring continuity in financial management during the search for a new CFO and mitigating potential risks associated with executive turnover.
- CFO Recruitment Initiative: Certara has engaged a leading executive search firm to identify its next CFO, reflecting the company's commitment to a thorough selection process aimed at finding a suitable candidate to support future financial strategies and business growth.
- Market Reaction Anticipation: Given that executive changes may raise concerns about the company's future financial performance, Certara must implement measures to stabilize investor confidence before the new CFO is appointed to maintain its competitive position in the healthcare sector.
See More
Certara CFO John Gallagher Resigns, Interim CFO Appointed
- Executive Change: Certara's CFO John Gallagher has announced his resignation effective July 14, 2026, marking a significant shift in the company's financial leadership that may impact investor confidence and financial stability.
- Interim Appointment: Faiz Mohammed, Senior Vice President of Finance and Treasurer, has been appointed as Interim CFO, bringing over 25 years of finance and accounting experience to ensure continuity in financial management during this transition.
- Guidance Reaffirmation: Certara reaffirms its 2026 financial guidance provided during the Q1 earnings call, demonstrating confidence in future performance despite the uncertainties introduced by the executive change.
- Market Reaction Anticipation: The resignation may lead to negative short-term market reactions for Certara, prompting investors to closely monitor the upcoming management transition and its implications for the company's strategic direction.
See More
CervoMed and Others See Significant Stock Gains
- CervoMed Clinical Progress: CervoMed's lead drug candidate Neflamapimod has completed enrollment in its Phase 2a trial in the US, with 24-week biomarker data expected in Q4 2023, which will significantly bolster its market potential in treating dementia.
- Conexeu Leadership Expansion: Conexeu Sciences expanded its board from six to nine members and appointed a Chief Commercial Officer to accelerate the development of its 3D-printed bioregenerative breast matrix, aiming to enhance market execution and growth potential.
- NeOnc International Regulatory Approval: NeOnc Technologies received regulatory clearance from the Department of Health - Abu Dhabi to initiate a Phase 2 trial of NEO212 for aggressive brain tumors, marking a significant step in its international development and enhancing its competitive position.
- Simulations Plus Acquisition Agreement: Simulations Plus has agreed to be acquired by Altaris for $375 million, with shareholders set to receive $18.50 per share, representing a premium, and the transaction is expected to close in Q4 2023, providing new capital and resources for future growth.
See More
Investigation Launched into Certara by Law Firm for Investor Claims
- Declining Financial Performance: Certara reported a 4% year-over-year decline in services revenue to $57.2 million and a 14% drop in services bookings to $66.6 million in its Q1 2026 results, raising concerns among investors about potential future revenue growth challenges.
- Weak Customer Performance: The company noted softer performance from Tier 1 customers in MIDD services, describing overall service performance as 'mixed', indicating challenges in maintaining customer relationships and market competitiveness, which could impact its market share.
- Exit from Regulatory Business: Certara announced its exit from the regulatory business within its services segment, a strategic shift that may further affect the company's revenue structure and business diversity, increasing uncertainty regarding its future growth prospects.
- Significant Stock Price Drop: Following the earnings report, Certara's stock price plummeted from $6.31 to $5.13 per share, a decline of approximately 19%, reflecting market concerns over the company's financial health and potentially diminishing investor confidence.
See More
Investigation into Certara Investor Losses Announced
- Financial Performance Decline: Certara reported a 4% year-over-year decline in services revenue to $57.2 million and a 14% drop in services bookings to $66.6 million in Q1 2026, indicating weak performance among Tier 1 customers that could hinder future revenue growth.
- Execution Challenges: The company acknowledged execution and go-to-market challenges in its services business, with inconsistencies between software and services performance, reflecting difficulties in business integration and responsiveness to customer demands, which may erode investor confidence.
- Executive Transition: On June 17, 2026, Certara announced CFO John Gallagher's resignation effective July 14, 2026, with Faiz Mohammed stepping in as Interim CFO, raising concerns about management stability that could further impact stock prices.
- Legal Investigation Initiated: Johnson Fistel is investigating whether Certara complied with federal securities laws, and if investors suffered losses from holding Certara stock, they may seek compensation through legal channels, potentially damaging the company's reputation and shareholder trust.
See More
Certara CFO John Gallagher to Resign in 2026
- Executive Change: Certara's CFO John Gallagher has announced his resignation effective July 14, 2026, indicating potential instability at the executive level, which may impact investor confidence.
- Interim Appointment: Faiz Mohammed will serve as interim CFO; currently the Senior VP of Finance, he brings over 25 years of finance and accounting experience, expected to provide transitional support during this period.
- Stock Price Fluctuation: Certara shares closed at $6.03, down 0.33%, and traded at $5.88 in the overnight market, reflecting a 2.49% decline, indicating market concerns regarding the executive change.
- Market Reaction: The resignation news may prompt investors to reassess Certara's future financial performance, potentially putting pressure on the stock price in the short term and affecting the company's competitiveness in the biotech sector.
See More
Certara CFO John Gallagher Announces Resignation Effective July 14, 2026
- Executive Change: Certara's CFO John Gallagher has announced his resignation effective July 14, 2026, indicating a significant shift in the company's financial leadership that could impact investor confidence and the stability of its financial strategy.
- Interim Leadership: Following Gallagher's departure, Faiz Mohammed, Certara's Senior Vice President of Finance and Treasurer, will serve as interim CFO, ensuring continuity in financial management during the search for a new CFO and mitigating potential risks associated with executive turnover.
- CFO Recruitment Initiative: Certara has engaged a leading executive search firm to identify its next CFO, reflecting the company's commitment to a thorough selection process aimed at finding a suitable candidate to support future financial strategies and business growth.
- Market Reaction Anticipation: Given that executive changes may raise concerns about the company's future financial performance, Certara must implement measures to stabilize investor confidence before the new CFO is appointed to maintain its competitive position in the healthcare sector.
See More
Certara CFO John Gallagher Resigns, Interim CFO Appointed
- Executive Change: Certara's CFO John Gallagher has announced his resignation effective July 14, 2026, marking a significant shift in the company's financial leadership that may impact investor confidence and financial stability.
- Interim Appointment: Faiz Mohammed, Senior Vice President of Finance and Treasurer, has been appointed as Interim CFO, bringing over 25 years of finance and accounting experience to ensure continuity in financial management during this transition.
- Guidance Reaffirmation: Certara reaffirms its 2026 financial guidance provided during the Q1 earnings call, demonstrating confidence in future performance despite the uncertainties introduced by the executive change.
- Market Reaction Anticipation: The resignation may lead to negative short-term market reactions for Certara, prompting investors to closely monitor the upcoming management transition and its implications for the company's strategic direction.
See More
CervoMed and Others See Significant Stock Gains
- CervoMed Clinical Progress: CervoMed's lead drug candidate Neflamapimod has completed enrollment in its Phase 2a trial in the US, with 24-week biomarker data expected in Q4 2023, which will significantly bolster its market potential in treating dementia.
- Conexeu Leadership Expansion: Conexeu Sciences expanded its board from six to nine members and appointed a Chief Commercial Officer to accelerate the development of its 3D-printed bioregenerative breast matrix, aiming to enhance market execution and growth potential.
- NeOnc International Regulatory Approval: NeOnc Technologies received regulatory clearance from the Department of Health - Abu Dhabi to initiate a Phase 2 trial of NEO212 for aggressive brain tumors, marking a significant step in its international development and enhancing its competitive position.
- Simulations Plus Acquisition Agreement: Simulations Plus has agreed to be acquired by Altaris for $375 million, with shareholders set to receive $18.50 per share, representing a premium, and the transaction is expected to close in Q4 2023, providing new capital and resources for future growth.
See More
